News & Insights

Person

Date

  • Filter by dates

Active filters:

05.07.2023

We advised WSE-listed Bioceltix S.A. on a non-brokered public offering of the Company's shares

We advised WSE-listed Bioceltix S.A. on a non-brokered public offering of the Company's shares carried out under the accelerated book-building (ABB) p...

Case studies
NEW!
We advised WSE-listed Bioceltix S.A. on a non-brokered public offering of the Company’s shares

26.06.2023

We advised WSE-listed Pure Biologics S.A. on a PLN 12 million financing transaction

We advised WSE-listed Pure Biologics S.A. in a transaction to raise PLN 12 million in financing from a new investor, ACRX Investments Ltd. The transaction was executed ...

Case studies
We advised WSE-listed Pure Biologics S.A. on a PLN 12 million financing transaction

23.06.2023

We advised WSE-listed Genomtec S.A. on a non-brokered public offering

We advised WSE-listed Genomtec S.A. on a non-brokered public offering of the company's shares carried out under an accelerated bookbuilding procedure (ABB) and a related...

News
We advised WSE-listed Genomtec S.A. on a non-brokered public offering

23.06.2023

We advised the WSE-listed Genomtec S.A. on its prospect-free IPO

We advised the WSE-listed Genomtec S.A. on a prospect-free public offering of the company's shares carried out under the accelerated bookbuilding procedure (ABB) and a r...

Case studies
We advised the WSE-listed Genomtec S.A. on its prospect-free IPO

20.03.2023

GESSEL advises Urteste S.A. on a public placement of new issue shares and on transfer of its shares

GESSEL advises Urteste S.A. on a public placement of new issue shares and on transfer of its shares from the NewConnect alternative trading system to the main floor of t...

Case studies
GESSEL advises Urteste S.A. on a public placement of new issue shares and on transfer of its shares

Do you want to be up to date?

Subscribe to the newsletter!